(131)I treatment for thyroid cancer and risk of developing primary hyperparathyroidism: a cohort study.


Lin, CM; Doyle, P; Tsan, YT; Lee, CH; Wang, JD; Chen, PC; Health Data Analysis in Taiwan (hDATa) Research Group, ; (2013) (131)I treatment for thyroid cancer and risk of developing primary hyperparathyroidism: a cohort study. European journal of nuclear medicine and molecular imaging. ISSN 1619-7070 DOI: https://doi.org/10.1007/s00259-013-2541-5

Full text not available from this repository.

Abstract

PURPOSE To evaluate the association between (131)I therapy for thyroid cancer and risk of developing primary hyperparathyroidism. METHODS This was a nationwide population-based cohort study of patients with thyroid cancer diagnosed during the period 1997-2008. The data were obtained from the Taiwan National Health Insurance Research dataset. The cumulative (131)I dose in each patient was calculated. Hazard ratios (HRs) were calculated using a proportional hazards model to estimate the effect of (131)I therapy on the risk of developing primary hyperparathyroidism in the cohort. RESULTS A total of 8,946 patients with thyroid cancer were eligible for the final analysis. Among these patients, 8 developed primary hyperparathyroidism during the follow-up period that represented 38,248 person-years giving an incidence rate of 20.9 per 10(5) person-years. (131)I was used in the treatment of 6,153 patients (68.8 %) with a median cumulative dose of 3.7 GBq. The adjusted HRs were 0.21 (95% CI 0.02-1.86) and 0.46 (95% CI 0.10-2.10) for those receiving a cumulative (131)I dose of 0.1-3.6 GBq and ≥3.7 GBq, respectively, compared to no therapy. The risk of developing primary hyperparathyroidism did not increase with increasing (131)I dose (test for trend p = 0.51). No interaction was found between (131)I dose and age (p = 0.94) or (131)I dose and sex (p = 0.99). CONCLUSION (131)I treatment for thyroid cancer did not increase risk of primary hyperparathyroidism during a 10-year follow-up in this study population. Further research with a longer follow-up period is needed to assess late adverse effects beyond 10 years.

Item Type: Article
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Non-Communicable Disease Epidemiology
Research Centre: Centre for Global Non-Communicable Diseases (NCDs)
PubMed ID: 23982456
Web of Science ID: 329639300010
URI: http://researchonline.lshtm.ac.uk/id/eprint/1440415

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
278Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item